Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACET

Adicet Bio Inc

Oct 27 • 01:57PM ET

0.8587

-0.0313 -3.52 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP FATE NTLA ALLO AGIO GILD BLUE EDIT IMTX SGMO

| Held by: VTI VXF BTEC CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.30	Insider Own	25.11%	Shs Outstand	153.25M	Perf Week	-13.16%
Market Cap	131.60M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	14.93%	Shs Float	114.78M	Perf Month	2.22%
Enterprise Value	22.00M	PEG	-	EPS next Q	-0.29	Inst Own	23.22%	Short Float	6.44%	Perf Quarter	22.12%
Income	-118.64M	P/S	-	EPS this Y	15.28%	Inst Trans	-5.99%	Short Ratio	5.88	Perf Half Y	38.51%
Sales	0.00M	P/B	0.54	EPS next Y	20.37%	ROA	-54.95%	Short Interest	7.39M	Perf YTD	-10.74%
Book/sh	1.60	P/C	1.05	EPS next 5Y	19.33%	ROE	-64.39%	52W High	1.48 -41.98%	Perf Year	-40.37%
Cash/sh	0.82	P/FCF	-	EPS past 3/5Y	12.69% 36.74%	ROIC	-81.38%	52W Low	0.45 92.05%	Perf 3Y	-94.80%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.42% 10.25%	Perf 5Y	-93.49%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	48.45%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.48	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.55	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	7.48	EPS Q/Q	-3.88%	SMA20	-6.39%	Beta	1.63	Target Price	6.33
Payout	-	Debt/Eq	0.12	Sales Q/Q	-	SMA50	3.66%	Rel Volume	3.02	Prev Close	0.89
Employees	152	LT Debt/Eq	0.09	Earnings	Aug 07 AMC	SMA200	11.40%	Avg Volume	1.26M	Price	0.86
IPO	Jan 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.88% -	Trades		Volume	2,659,224	Change	-3.52%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-24	Resumed	Guggenheim	Buy	$7
Sep-11-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-27-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-23	Downgrade	Guggenheim	Buy → Neutral
Jun-01-23	Downgrade	JP Morgan	Overweight → Neutral	$20 → $6
Sep-21-22	Initiated	JP Morgan	Overweight	$23
Mar-31-22	Initiated	SMBC Nikko	Outperform	$28
Mar-08-22	Initiated	Truist	Buy	$30
Mar-04-22	Initiated	Jefferies	Buy	$27
May-18-21	Initiated	BTIG Research	Buy	$34
Apr-23-21	Initiated	H.C. Wainwright	Buy	$27
Apr-14-21	Initiated	Canaccord Genuity	Buy	$28
Apr-08-21	Initiated	Guggenheim	Buy	$22
Nov-04-20	Initiated	B. Riley Securities	Buy	$30
Oct-27-20	Initiated	JMP Securities	Mkt Outperform	$30
Oct-16-20	Initiated	Wedbush	Outperform	$25

Show Previous Ratings

Oct-16-25 07:00AM	Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) (Business Wire) +5.49%
Oct-07-25 09:40AM	Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? (Zacks) -14.69%
07:01AM	Adicet Bio, Inc. Announces $80 Million Registered Direct Offering (Business Wire)
06:45AM	Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) (Business Wire)
Sep-30-25 04:27PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:00PM	Loading…
12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-02-25 07:00AM	Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-29-25 04:48PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.09%
Aug-12-25 12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's Why (Zacks) +7.14%
Aug-07-25 04:01PM	Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire) -9.62%
Aug-06-25 04:05PM	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference (Business Wire)
Aug-04-25 08:05AM	MaxCyte Signs Platform License Agreement with Adicet Bio (GlobeNewswire)
Jul-25-25 07:27AM	Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001 (Clinical Trials Arena)
Jul-24-25 07:00AM	Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
04:00PM	Loading…
May-21-25 04:00PM	Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference (Business Wire) -6.59%
May-09-25 12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know (Zacks) +27.49%
May-06-25 04:01PM	Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire) -9.44% -18.65%
Apr-30-25 04:47PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.41% -5.07%
07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
Apr-28-25 04:30PM	Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (Business Wire) +5.82%
Apr-17-25 07:00AM	Adicet Bio Appoints Michael Grissinger to the Board of Directors (Business Wire) -7.96%
Mar-31-25 05:12PM	Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.06%
07:00AM	Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Mar-23-25 08:43AM	Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-06-25 04:01PM	Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress (Business Wire) -5.90%
Mar-03-25 07:00AM	Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting (Business Wire) -5.70%
Feb-27-25 08:36AM	Adicet Bio shares rise on FDA Fast Track Designation for ADI-001 (Investing.com)
07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) (Business Wire)
Feb-05-25 07:10AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement (Business Wire) +9.79%
06:06PM	Loading…
Jan-31-25 06:06PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-29-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (Business Wire)
Jan-08-25 04:10PM	Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones (Business Wire)
Dec-31-24 04:48PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.81%
Dec-19-24 07:00AM	Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire)
Dec-18-24 07:00AM	Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer (Business Wire) -6.28%
Nov-29-24 04:44PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 04:00PM	Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +6.42%
07:00AM	Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
Nov-16-24 09:00AM	Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-06-24 04:00PM	Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Nov-05-24 07:00AM	Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-01-24 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-24 05:31PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.88%
Oct-17-24 07:27AM	Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials (TipRanks)
Oct-16-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome (Business Wire) +6.43%
Sep-30-24 05:08PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference (Business Wire)
07:00AM	Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases (Business Wire)
Sep-19-24 07:00AM	ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue (Business Wire)
Aug-30-24 05:44PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-27-24 04:00PM	Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) -7.84%
Aug-19-24 07:00AM	Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors (Business Wire)
Aug-13-24 07:00AM	Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Aug-01-24 04:00PM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 05:25PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-24 01:24AM	Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds? (Insider Monkey)
Jul-09-24 09:52AM	Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag (Zacks)
07:34AM	Adicet Bio's ADI-270 receives FDA Fast Track Designation for kidney cancer treatment (Pharmaceutical Business Review)
Jul-08-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +9.35%
Jun-28-24 05:00PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.70%
Jun-24-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma (Business Wire) +9.49%
Jun-21-24 11:10AM	Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
Jun-05-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis (Business Wire) +5.88%
May-31-24 05:41PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference (Business Wire) -7.05%
May-14-24 09:54PM	ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024 (InvestorPlace) -7.64% +5.26%
04:01PM	Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
10:00AM	Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
May-07-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
Apr-30-24 05:10PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.29%
Apr-22-24 04:30PM	Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (Business Wire)
Apr-08-24 07:00AM	Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Apr-04-24 08:38AM	Why Adicet Bio (ACET) Stock Might be a Great Pick (Zacks)
Apr-01-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-24 05:19PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-22-24 09:35AM	Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +7.35%
Mar-19-24 09:53PM	ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023 (InvestorPlace) +5.42%
04:10PM	Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Mar-15-24 09:40AM	Are Medical Stocks Lagging Adicet Bio (ACET) This Year? (Zacks)
Mar-11-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 07:46PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-28-24 09:40AM	Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-12-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-05-24 04:01PM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-31-24 04:39PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-30-24 12:51PM	Hedge Fund and Insider Trading News: Larry Robbins, Ray Dalio, Two Sigma Investments, Point72 Asset Management, Bluebell Capital Partners, Adicet Bio Inc (ACET), Netflix, Inc. (NFLX), and More (Insider Monkey)
Jan-25-24 04:01PM	Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (Business Wire)
09:40AM	Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-22-24 11:43PM	Adicet Bio, Inc. Announces Pricing of Public Offering (Business Wire)
04:28PM	Adicet Bio, Inc. Announces Proposed Public Offering (Business Wire)
Jan-04-24 07:00AM	Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 (Business Wire) +22.73%
Jan-03-24 04:01PM	Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook (Business Wire) -12.44%
Dec-29-23 04:50PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.62% +6.35%
Dec-10-23 12:00PM	Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting (Business Wire)
Nov-08-23 04:10PM	Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates (Business Wire) -6.02%
Nov-07-23 07:00AM	Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference (Business Wire) -8.04%
Nov-02-23 09:00AM	Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting (Business Wire) +13.85%

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of "off-the-shelf" gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	10% Owner	Oct 08 '25	Buy	1.00	5,000,000	5,000,000	9,026,359	Oct 10 08:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACET

Adicet Bio Inc

Upgrade your FINVIZ experience